Key result
Spironolactone added to ACEI and/or ARB therapy significantly decreased 24-hour urine protein levels compared to control (1.59 vs 1.78 g/day, P<0.05) in patients with chronic glomerular disease.
Why the study?
Does spironolactone reduce urine protein levels in patients with chronic glomerular disease receiving ACEIs and/or ARBs?
Population
221 patients with chronic glomerular disease, mean age ~34, China-based. Key inclusion criteria: history of…
Comparison
Spironolactone 20 mg/day added to the original… vs Original doses of ACEIs and/or ARBs alone.
Design
RCT, open, randomized method, open
Follow-up
16 weeks
Authors
Loading...
Supports adding spironolactone to ACEI/ARB for proteinuria reduction in glomerular disease; extends MRA evidence in proteinuric CKD.
RCT (n=221)
Open-label
Open, randomized method
No
Does spironolactone reduce urine protein levels in patients with chronic glomerular disease receiving ACEIs and/or ARBs?
Absolute Event Rate: 1.59% vs 1.78%
p-value: p=<0.05
The addition of low-dose spironolactone to ACEI and/or ARB therapy significantly reduces urine protein levels in patients with chronic glomerular disease.
Wang et al. (2013) conducted an RCT in Chronic glomerular disease (n=221). Spironolactone vs. Original dosages of ACEI and/or ARB alone was evaluated on 24-hour urine protein level at 16 weeks (g/day) (p=<0.05). Spironolactone added to ACEI and/or ARB therapy significantly decreased 24-hour urine protein levels compared to control (1.59 vs 1.78 g/day, P<0.05) in patients with chronic glomerular disease.
Synapse has enriched one closely related paper. Consider it for comparative context: